{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:06:11Z","timestamp":1778126771963,"version":"3.51.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the effect of intraocular pressure-lowering medications on treatment outcomes in the Comparison of AMD Treatments Trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Secondary analysis of Comparison of AMD Treatments Trials data. Medication logs were reviewed for continuous 2-year use of agents that increased aqueous outflow (Group A: topical prostaglandins) or suppressed aqueous production (Group B: topical beta blockers and carbonic anhydrase inhibitors). Eyes were excluded if mixed-mechanism intraocular pressure\u2013lowering agents or medications from more than one group were taken. Anatomical and vision responses to treatment at years 1, 2, and over the entire 2-year period in each group were compared with controls (no intraocular pressure\u2013lowering medications).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Inclusion criteria were met by 28 Group A patients, 19 Group B patients, and 857 controls. After 2 years, the control group had a mean visual acuity improvement of +6.3 letters from baseline, compared with +3.5 letters in Group A (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.38), and +13.8 letters in Group B (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.052). Mean retinal thickness change from baseline was \u221254.9 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in controls, \u221280.6 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in Group A (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.26), and \u221296.8 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in Group B (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.13). Mean total thickness change from baseline was \u2212163 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in controls, \u2212180 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in Group A (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.63), and \u2212238 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m in Group B (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.08). In longitudinal analysis with adjustment by their baseline values, anti\u2013vascular endothelial growth factor treatment drug and regimen, Group B had more visual acuity improvement (difference of 2.6 letters, 95% confidence interval: \u22123.4\u20138.5 letters), more reduction in the retinal thickness (\u221217.9 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m, 95% confidence interval: \u221236.5 to 0.7 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m), and total thickness from baseline (mean difference of \u221254.7 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m, 95% confidence interval: \u2212103 to 6.2 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m) compared with the control group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Concurrent aqueous suppressant use during anti\u2013vascular endothelial growth factor therapy for neovascular age-related macular degeneration was associated with a trend toward greater reductions in retinal and total thickness as well as improved visual outcomes over 2 years. A similar effect was not observed to the same extent with agents that increase aqueous outflow. Because of the small sample size and secondary analysis, these findings must be cautiously interpreted and perhaps serve as a basis for future prospective studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002124","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T20:47:06Z","timestamp":1520369226000},"page":"636-647","source":"Crossref","is-referenced-by-count":6,"title":["EFFECT OF INTRAOCULAR PRESSURE\u2013LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS"],"prefix":"10.1097","volume":"39","author":[{"given":"Ehsan","family":"Rahimy","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California;"},{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the CATT Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results","volume":"119","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heir","year":"2012","journal-title":"Ophthalmology"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","article-title":"Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (timolol-dorzolamide)","volume":"247","author":"Byeon","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/IAE.0b013e318158ea28","article-title":"Predicted biologic activity of intravitreal bevacizumab","volume":"27","author":"Stewart","year":"2007","journal-title":"Retina"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","article-title":"Topical dorzolamide-timolol with intravitreous anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"134","author":"Sridhar","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","article-title":"Photographic assessment of baseline fundus morphologic features in the comparison of age-related macular degeneration treatments trials","volume":"119","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.ophtha.2012.06.040","article-title":"Optical coherence tomography grading reproducibility during the comparison of age-related macular degeneration treatments trials","volume":"119","author":"DeCroos","year":"2012","journal-title":"Ophthalmology"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/09286586.2016.1259636","article-title":"Tutorial on biostatistics: linear regression analysis of continuous correlated eye data","volume":"24","author":"Ying","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0161-6420(99)00044-5","article-title":"Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects","volume":"107","author":"Brubaker","year":"2000","journal-title":"Ophthalmology"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of \u03b2-adrenoreceptor blockade","volume":"52","author":"Ristori","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","article-title":"Antiangiogenic effects of \u03b22-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy","volume":"119","author":"Martini","year":"2011","journal-title":"J Neurochem"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.preteyeres.2014.06.001","article-title":"The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases","volume":"42","author":"Casini","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2013.1476","article-title":"Attenuation of choroidal neovascularization by \u03b22-adrenoreceptor antagonism","volume":"131","author":"Lavine","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/IAE.0b013e3182695ba0","article-title":"Systemic \u03b2-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab","volume":"33","author":"Montero","year":"2013","journal-title":"Retina"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/IAE.0000000000001226","article-title":"Systemic beta blockers in neovascular age-related macular degeneration","volume":"37","author":"Traband","year":"2017","journal-title":"Retina"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2014.03.005","article-title":"Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study","volume":"121","author":"Klein","year":"2014","journal-title":"Ophthalmology"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1097\/IAE.0000000000000603","article-title":"Effect of systemic \u03b2-blockers, ACE inhibitors, and angiotensin receptor blockers on development of choroidal neovascularization in patients with age-related macular degeneration","volume":"35","author":"Thomas","year":"2015","journal-title":"Retina"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2005.12.030","article-title":"Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa","volume":"141","author":"Grover","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00417-011-1904-5","article-title":"The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa","volume":"250","author":"Ikeda","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archophthalmol.2009.398","article-title":"Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis","volume":"128","author":"Genead","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/IAE.0b013e3182215ae9","article-title":"Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia","volume":"32","author":"Genead","year":"2012","journal-title":"Retina"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/eye.2012.228","article-title":"Topical dorzolamide therapy for taxane-related macular oedema","volume":"27","author":"Ehlers","year":"2013","journal-title":"Eye (Lond)"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/ICB.0000000000000433","article-title":"Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema","volume":"12","author":"Dwivedi","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"R33-20230816","first-page":"142","article-title":"Membrane-bound carbonic anhydrase activity in the rat corneal endothelium and retina","volume":"40","author":"Terashima","year":"1996","journal-title":"Jpn J Ophthalmol"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1085\/jgp.200810169","article-title":"CO2-induced ion and fluid transport in human retinal pigment epithelium","volume":"133","author":"Adijanto","year":"2009","journal-title":"J Gen Physiol"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-0420.1996.tb00737.x","article-title":"Effects of topical dorzolamide on retinal and retrobulbar hemodynamics","volume":"74","author":"Harris","year":"1996","journal-title":"Acta Ophthalmol Scand"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0002-9394(01)01158-8","article-title":"Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma","volume":"132","author":"Harris","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bjo.87.6.753","article-title":"The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration","volume":"87","author":"Harris","year":"2003","journal-title":"Br J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201904000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:15:18Z","timestamp":1692231318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201904000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002124","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}